Compare FOR & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | BHVN |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2007 | 2022 |
| Metric | FOR | BHVN |
|---|---|---|
| Price | $24.98 | $9.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $31.75 | $28.85 |
| AVG Volume (30 Days) | 108.9K | ★ 2.1M |
| Earning Date | 04-21-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,662,400,000.00 | N/A |
| Revenue This Year | $0.52 | N/A |
| Revenue Next Year | $7.72 | N/A |
| P/E Ratio | $81.50 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $18.00 | $7.48 |
| 52 Week High | $30.74 | $24.06 |
| Indicator | FOR | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 48.62 |
| Support Level | $24.20 | $9.41 |
| Resistance Level | $26.06 | $10.28 |
| Average True Range (ATR) | 0.79 | 0.59 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 38.60 | 61.54 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.